Contrast-enhanced ultrasonography–CT/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: improving feasibility and therapeutic outcome

医学 射频消融术 放射科 经皮 烧蚀 超声造影 肝肿瘤 肝细胞癌 超声波 超声科 内科学
作者
Yuna Lee,Jeong Hee Yoon,Seung-Wan Han,Ijin Joo,Jeong Min Lee
出处
期刊:Cancer Imaging [BioMed Central]
卷期号:24 (1)
标识
DOI:10.1186/s40644-023-00650-y
摘要

Percutaneous radiofrequency ablation (RFA) is pivotal for treating small malignant liver tumors, but tumors often remain inconspicuous on B-mode ultrasound (US). This study evaluates the potential of CEUS-CT/MRI fusion imaging (FI) to improve tumor visibility and the associated RFA outcomes for small (≤ 3 cm) malignant liver tumors that were inconspicuous on US.Between January 2019 and April 2021, a prospective study enrolled 248 patients with liver malignancies (≤ 3 cm) that were poorly visible on B-mode US. Tumor visibility and ablation feasibility were assessed using B-mode US, US-CT/MRI FI, and CEUS-CT/MRI FI, and graded on a 4-point scale. CEUS was employed post-registration of US and CT/MRI images, utilizing either SonoVue or Sonazoid. Comparisons between US-based and CEUS-based fusion visibility and feasibility scores were undertaken using the Friedman test. Moreover, rates of technical success, technique efficacy, local tumor progression (LTP), and major complications were assessed.The cohort included 223 hepatocellular carcinomas (HCCs) (89.9%) and 23 metastases (9.3%), with an average tumor size of 1.6 cm. CEUS-CT/MRI FI demonstrated a significant advantage in tumor visibility (3.4 ± 0.7 vs. 1.9 ± 0.6, P < 0.001) and technical feasibility (3.6 ± 0.6 vs. 2.9 ± 0.8, P < 0.001) compared to US-FI. In 85.5% of patients, CEUS addition to US-FI ameliorated tumor visibility. Technical success was achieved in 99.6% of cases. No severe complications were reported. One and two-year post CEUS-CT/MRI FI-guided RFA estimates for LTP were 9.3% and 10.9%, respectively.CEUS-CT/MRI FI significantly improves the visualization of tumors not discernible on B-mode US, thus augmenting percutaneous RFA success and delivering improved therapeutic outcomes.ClinicalTrials.gov, NCT05445973. Registered 17 June 2022 - Retrospectively registered, http://clinicaltrials.gov/study/NCT05445973?id=NCT05445973&rank=1 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
爆米花应助析界成微采纳,获得10
2秒前
2秒前
2秒前
季恒恒发布了新的文献求助10
3秒前
Ava应助zimuzi采纳,获得10
3秒前
4秒前
tyzz发布了新的文献求助10
4秒前
ecos完成签到,获得积分10
4秒前
molihuakai应助ys1122采纳,获得10
4秒前
隐形曼青应助利嘉皮采纳,获得10
5秒前
福宝完成签到,获得积分20
5秒前
赟yun完成签到,获得积分0
6秒前
7秒前
li发布了新的文献求助10
7秒前
Jeffrey2026完成签到,获得积分10
7秒前
8秒前
小半发布了新的文献求助10
8秒前
8秒前
玖月发布了新的文献求助10
8秒前
yxsoon完成签到,获得积分10
8秒前
phil完成签到,获得积分10
9秒前
wangzheng发布了新的文献求助10
9秒前
贼佛的小德完成签到 ,获得积分10
9秒前
9秒前
9秒前
令狐梦柏发布了新的文献求助10
9秒前
tigger发布了新的文献求助10
10秒前
就这发布了新的文献求助10
11秒前
beastye完成签到,获得积分20
12秒前
13秒前
tyzz完成签到,获得积分10
13秒前
肚肚肚发布了新的文献求助10
13秒前
13秒前
李健的小迷弟应助2752543083采纳,获得10
13秒前
CipherSage应助ZKL采纳,获得10
14秒前
江楠发布了新的文献求助10
15秒前
Lucas应助Tao采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Cronologia da história de Macau 5000
Petrology and Plate Tectonics 800
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
Electrode Potentials 550
Handbook Of Synthetic Methodologies And Protocols Of Nanomaterials 500
Trees of tropical Asia : an illustrated guide to diversity 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 光电子学 物理化学 电极 基因 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 6982808
求助须知:如何正确求助?哪些是违规求助? 8661375
关于积分的说明 18364414
捐赠科研通 6447675
什么是DOI,文献DOI怎么找? 3094117
关于科研通互助平台的介绍 2151567
邀请新用户注册赠送积分活动 2070291